Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions

Details for Australian Patent Application No. 2004213858 (hide)

Owner MacroPore Biosurgery, Inc.

Inventors Strem, Brian M.; Hedrick, Marc H.; Zhu, Min; Daniels, Eric; Fraser, John K.; Wulur, Isabella

Agent Spruson & Ferguson

Pub. Number AU-B-2004213858

PCT Pub. Number WO2004/074457

Priority 60/462,911 15.04.03 US; 60/449,279 20.02.03 US

Filing date 20 February 2004

Wipo publication date 2 September 2004

Acceptance publication date 22 January 2009

International Classifications

A01N 63/00 (2006.01) Biocides, pest repellants or attractants, or plant growth regulators containing micro-organisms, viruses, microbial fungi, animals, e.g. nematodes, or substances produced by, or obtained from micro-organisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates

C12N 5/00 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines

C12N 5/06 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines -

A61K 35/12 (2006.01) Medicinal preparations containing material or reaction products thereof with undetermined constitution - Materials from mammals or birds

Event Publications

13 October 2005 PCT application entered the National Phase

  PCT publication WO2004/074457 Priority application(s): WO2004/074457

22 January 2009 Application Accepted

  Published as AU-B-2004213858

21 May 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004213859-N-acetylglucosaminyltransferase III expression in lower eukaryotes

2004213855-Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes